Introduction {#s1}
============

Mast cells are primary immune cells with pivotal roles in allergic inflammatory reactions ([@B46]). Mast cells secrete a wide range of biological mediators, which collectively account for the pathology of allergic inflammation ([@B44]). These include preformed secretory granules (containing histamine and proteases) as well as cytokines, chemokines, and growth factors, which are synthesized upon mast cell activation ([@B6]). Among these, histamine acts as an important mediator of allergic inflammation by stimulating vasodilation, vascular permeability, hypothermia, and recruitment of leukocytes ([@B9]). Furthermore, mast cells secrete pro-inflammatory cytokines contributing the progression of allergic inflammatory reactions ([@B32]; [@B44]).

Mast cell activation is triggered by cross-linking of membrane-bound immunoglobulin E (IgE) with FcεRI, the high-affinity IgE receptor ([@B13]). Aggregation of FcεRI is associated with activation of the Src family protein-tyrosine kinase (PTK), Lyn, which subsequently phosphorylates Syk ([@B12]). FcεRI-mediated signaling also activates another PTK, Fyn, which enhances Syk activation. This is followed by activation of Grb2-associated binding protein 2 and phosphoinositide 3-kinase (PI3K) ([@B13]). Therefore, both PTKs are important for activation of various signaling pathways, including the PI3K, phospholipase C (PLC)γ, Akt, and nuclear factor (NF)-κB pathways. These signaling events lead to the initiation of inflammatory responses *via* intracellular calcium release, degranulation, and cytokine secretion ([@B41]).

Intracellular calcium release leads to mast cell degranulation and cytokine production in allergic inflammation ([@B4]). FcεRI-mediated activation of PLCγ generates inositol triphosphate (IP3) and diacylglycerol (DAG), which are essential factors for intracellular calcium release and mast cell degranulation. In addition, various studies have reported that calcium releases triggers secretion of inflammatory cytokines, which is mediated by nuclear translocation of NF-κB ([@B16]; [@B22]; [@B19]). Nuclear translocation of NF-κB mediates the production of inflammatory cytokines, especially tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 ([@B13]; [@B20]). Thus, inhibition of FcεRI-mediated activation of Lyn, Fyn, and intracellular calcium levels are considered as potential therapeutic strategy in mast cell--mediated allergic inflammation.

The fruit of *Schisandra chinensis* (Turcz). Baill. (*Schisandraceae*) is well-known in traditional Chinese medicine and Western herbal medicine and is widely used for the treatment of cough, asthma, diaphoresis, rheumatism, and arthritis ([@B23]; [@B18]). Several studies have demonstrated that *S. chinensis* exhibits diverse pharmacological effects, including anti-allergic, anti-inflammatory, anti-oxidant, anti-tumor, anti-viral, anti-bacterial, and hepatoprotective properties ([@B2]; [@B42]). *S. chinensis* consists of various bioactive constituents, including lignans, triterpenoids, polysaccharides, and sterols ([@B35]). Many active lignans have been extracted from this plant such as deoxyschisandrin, schisandrin, γ-schisandrin, and gomisin ([@B42]). Among these, schisandrin and gomisin N have been reported to possess anti-allergic inflammatory effects on mast cells ([@B23]; [@B2]). Gomisin M2 (G.M2) is one of the active lignin components of *S. chinensis* and has shown anti-HIV properties by inhibiting the replication of H9 lymphocytes and demonstrated cytotoxicity against MCF7 and CAL27 cancer cells ([@B3]; [@B15]). In addition, G.M2 has been considered a quality marker of a Chinese herbal formulae, Shengmai San, for protection against Alzheimer's disease ([@B48]). Based on the anti-allergic effects of other extracts isolated from *S. chinensis*, we hypothesize that G.M2 may have anti-allergic activity in mast cell--mediated allergic inflammation.

Materials and Methods {#s2}
=====================

Extraction, Isolation, and Identification of G.M2 {#s2_1}
-------------------------------------------------

Fruits of *S. chinensis* were purchased from the Yangnyeong herbal medicine market (Daegu, Republic of Korea). The specimen was identified by Prof. Jeong of the College of Pharmacy, Keimyung University, Republic of Korea, where a voucher specimen (No. KPP2018-1022) has been deposited. Fruits of *S. chinensis* (20 kg) were extracted with 95% ethanol (EtOH, 10 L) at room temperature for 5 days. The alcoholic extract was evaporated *in vacuo* to yield residue (5.7 kg), and the residue was suspended in H~2~O and successively partitioned with dichloromethane (CH~2~Cl~2~), ethyl acetate, and *n*-butanol. The CH~2~Cl~2~ extract (525 g) was subjected to silica gel column chromatography with a gradient of ether/acetone (20:1 to 1:2) to obtain five major fractions (Fr. 1--Fr. 5). Fr. 1 was subjected to Sephadex LH-20 elution with methanol/H~2~O (1:1), yielding two fractions (Fr. 1--1 and Fr. 1--2). Purification by semi-preparative high-performance liquid chromatography (HPLC) of Fr. 1--1 and Fr. 1--2 eluted with MeOH/H~2~O (10:1 to 1:1) yielded G.M~2~ (64 mg, yield 0.012%), schisandrin (902 mg, yield 0.171%), and gomisin A (752 mg, yield 0.143%) with a purity of at least 94.2%. G.M2 was identified, among the Fr. 1--2 isolates using ^1^H and ^13^C-NMR, respectively, and *via* a comparison of the generated spectral data with published data ([@B26]).

G.M~2~: HRESIMS m/z: 387 \[M+H\]^+^; ^1^H NMR (CDCl~3~, 500MHz): δH 6.45 (H-11), 5.93 (1-H, d, OCH~2~O), 3.80 (3-H, s, OMe-12), 3.57 (3-H, s, OMe-1), 3.49 (3-H, s, OMe-13), 2.42 (1-H, dd, J = 13.4, 7.7, H-9), 2.21 (1-H, dd, J = 13.4, 1.9, H-9), 1.98 (1-H, dd, J = 13.1, 9.3, H-6), 0.93 (3-H, d, J = 7.3, H-17), and 0.70 (3-H, d, J = 7.0, H-18); ^13^C NMR(CDCl~3~, 500MHz): δC 149.6 (C-12), 147.9 (C-3), 147.5 (C-14), 139.2 (C-1), 136.9 (C-5), 134.1 (C-2), 133.6 (C-13), 133.0 (C-10), 121.0 (C-16), 117.0 (C-15), 106.1 (C-11), 103.2 (C-4), 100.7 (OCH~2~O), 59.7 (OMe-13), 58.2 (OMe-1), 55.1 (OMe-12), 40.7 (C-7), 38.4 (C-9), 35.3 (C-6), 33.2 (C-8), 21.8 (C-17), and 12.8 (C-18).

Reagents and Cell Culture {#s2_2}
-------------------------

Anti-DNP IgE, DNP-human serum albumin (HSA), *o*-phthaldialdehyde (OPA), 4-nitrophenyl N-acetyl-β-D-glucosamide, dexamethasone (Dexa), and Histodenz™ were purchased from Sigma-Aldrich (St. Louis, MO). Alum adjuvant was procured from Thermo Scientific (Waltham, MA). Mouse bone marrow--derived mast cells (mBMMCs), rat basophilic leukemia cells (RBL-2H3, ATCC: CRL-2256), and rat peritoneal mast cells (RPMCs) were cultured at 5% CO~2~ in a 37°C atmosphere in Roswell Park Memorial Institute (RPMI)-1640 medium (Hyclone, Logan, UT), Dulbecco's Modified Eagle's medium, and α-minimum essential medium (Gibco, Grand Island, NY), respectively. These media were supplemented by 10% heat-inactivated fetal bovine serum (Gibco), 100 µg/ml streptomycin, 250 ng/ml amphotericin, and 100 U/ml penicillin G.

Preparation of mBMMCs {#s2_3}
---------------------

Mouse BMMCs were isolated from the femurs of male imprinting control region (ICR) mice as previously described ([@B19]). The isolated cells were grown in complete RPMI-1640 and supplemented with recombinant murine IL-3 and stem cell factor. After 4 weeks, fluorescence-activated cell sorting analysis was performed to evaluate surface markers and to confirm the mast cell purity. Cells expressing \> 90% of FcεRI^+^ and c-kit^+^ were used for experiments.

Preparation of RPMCs {#s2_4}
--------------------

RPMCs were isolated from two Sprague--Dawley (SD) rats as previously described ([@B20]). Isolated RPMCs were separated from other peritoneal cells by adding 1 ml of 0.235 g/ml Histodenz^™^ solution in cell solution followed by centrifuge filtration at 400 *g* for 15 min at room temperature. The supernatant containing other cells was discarded, and mast cells in the pellet were washed and resuspended. The purity and the viability of RPMCs were determined by toluidine blue (approximately 97%) and trypan blue (approximately 95%) staining.

Cell Viability {#s2_5}
--------------

Cell viability was measured using MTT Assay Kit (Welgene, Seoul, Korea) as described previously ([@B16]). Briefly, mBMMCs, RBL-2H3, and RPMCs (2 × 10^4^ cells/well in a 96-well plate) were treated with G.M2 (0.01--100 µM) for 8 h, followed by incubation with MTT reagent for 2 h. The formed formazan crystals were dissolved in dimethyl sulfoxide, and the absorbance was measured at 570 nm using a plate reader (Molecular Devices).

Histamine and β-Hexosaminidase Release {#s2_6}
--------------------------------------

Anti-DNP IgE (50 ng/ml)--sensitized mBMMCs, RBL-2H3, and RPMCs were pre-treated with or without G.M2 (0.1--10 µM) and then challenged with DNP-HSA (100 ng/ml) for 30 min, 4 h and 2 h, respectively. To measure histamine levels in blood serum and release media, 0.1 N HCl and 60% perchloric acid were added, followed by centrifugation. The supernatant was transferred, and 5 M NaCl, *n*-butanol, and 5 N NaOH were added. The solution was then vortexed and centrifuged again. In the next step, *n*-heptane and 0.1 N HCl were added to the supernatant, which was then vortexed and centrifuged. The histamine content was measured using an OPA spectrofluorometric procedure as previously described ([@B16]). The fluorescence intensity was detected at an excitation wavelength of 360 nm and an emission wavelength of 440 nm using a fluorescence plate reader (Molecular Devices). β-Hexosaminidase release in media was measured, as previously described ([@B19]). The absorbance was detected at 405 nm using a plate reader (Molecular Devices).

Intracellular Calcium {#s2_7}
---------------------

Fluo-3/AM (Invitrogen), a fluorescent indicator, was used to measure intracellular calcium levels. mBMMCs, RBL-2H3, and RPMCs were pre-incubated with Fluo-3/AM for 1 h, treated with or without G.M2 (0.1--10 µM) for 1 h, and then challenged with DNP-HSA (100 ng/ml). The fluorescence intensity was detected at an excitation wavelength of 485 nm and an emission wavelength of 520 nm as previously described ([@B19]). Intracellular calcium levels were compared to those of untreated control cells, which were set at a value of one relative fluorescent unit.

Quantitative Polymerase Chain Reaction (qPCR) {#s2_8}
---------------------------------------------

Anti-DNP IgE (50 ng/ml)--sensitized mBMMCs and RBL-2H3 were pre-treated with or without G.M2 (0.1--10 µM) and challenged with DNP-HSA (100 ng/ml) for 30 min and 1 h, respectively. Total cellular RNA was isolated, following the manufacturer's protocol (RNAiso Plus Kit, Takara Bio, Shiga, Japan). Quantitative PCR was used to measure the mRNA expression of TNF-α and IL-6, as previously described ([@B21]).

Enzyme-Linked Immunosorbent Assay (ELISA) {#s2_9}
-----------------------------------------

Anti-DNP IgE (50 ng/ml)--sensitized mBMMCs and RBL-2H3 were pre-treated with or without G.M2 for 1 h and then challenged with DNP-HSA (100 ng/ml) for 6 h. Cytokines levels were measured by ELISA Kits (BD Biosciences) according to the manufacturer's protocol. The substrate reaction was stopped, and the absorbance was measured using a spectrophotometer at a wavelength of 450 nm, as previously described ([@B16]).

Western Blot {#s2_10}
------------

Anti-DNP IgE (50 ng/ml)--sensitized mBMMCs were pre-treated with or without G.M2 for 1 h and then challenged with DNP-HSA (100 ng/ml) for 5 min (Lyn, Fyn, and Syk) and 15 min (PI3K, PLCγ1, Akt, IKK α/β, IκBα, and p65 NF-κB). Total protein was extracted as described previously ([@B19]). Equal amounts of protein were electrophoresed using 7.5--10% SDS-PAGE and transferred to a nitrocellulose membrane. The membrane was incubated with specific primary antibody followed by anti-IgG horse-radish peroxidase-conjugated secondary antibody. Immunodetection was performed using an enhanced chemiluminescence detection kit (Amersham, Piscataway, NJ).

Animals {#s2_11}
-------

Male ICR mice (30--35 g, 6 weeks old) and SD rats (240--280 g, 8 weeks old) were obtained from Dae-Han Experimental Animal Center (Daejeon, Korea). Throughout the study, animals (*n* = 5/cage) were provided with food and water *ad libitum* in a laminar air flow room maintained at 22 ± 2°C with a relative humidity of 55 ± 5% and 12-h light:dark cycles.

IgE-Mediated Passive Cutaneous Anaphylaxis (PCA) {#s2_12}
------------------------------------------------

The ear of each mouse was intradermally injected with 0.5 µg/site of anti-dinitrophenyl (DNP) IgE or phosphate buffered saline (PBS) and monitored for 48 h. G.M2 (0.1--10 mg/kg) or Dexa (10 mg/kg) were then administered orally. After 1 h, mice were challenged with a mixture of DNP-HSA (1 mg/mouse) and 4% Evans blue (1:1) *via* intravenous injection into the tail vein. The mice were euthanized 30 min after intravenous injection. Ear thickness and absorbance intensity were measured as previously described ([@B21]).

Ovalbumin (OVA)-Induced Active Systemic Anaphylaxis (ASA) {#s2_13}
---------------------------------------------------------

Each mouse was sensitized by repeated intraperitoneal injection of OVA mixture (100 µg of OVA and 2 mg of alum adjuvant) or PBS on days 0 and 7, as previously described ([@B21]). Subsequently, on days 9, 11, and 13, G.M2 (0.1--10 mg/kg) or Dexa (10 mg/kg) were administered orally. On day 14, mice were challenged with an intraperitoneal injection of 200 µg OVA, and rectal temperature was then monitored and recorded in at 10 min intervals for total of 90 min. Mice were euthanized after 90 min, and blood samples were collected from the abdominal artery for further experiments.

Statistical Analysis {#s2_14}
--------------------

All statistical data were analyzed using Prism statistical software (GraphPad Software, Inc). The results are expressed as the means ± SEM of three independent *in vitro* experiments and two independent *in vivo* experiments. Treatment effects were analyzed using one-way analysis of variance followed by Tukey's *post hoc* tests. *p* \< 0.05 was considered as statistically significant.

Results {#s3}
=======

Effects of G.M2 on Mast Cell Degranulation {#s3_1}
------------------------------------------

The chemical structure of G.M2 is displayed in [**Figure 1A**](#f1){ref-type="fig"}. To determine the anti-allergic effects of G.M2, we performed a degranulation assay based on the release of histamine and β-hexosaminidase in mBMMCs. We compared the inhibitory effect of G.M2 with known anti-allergic and major components of *S. chinensis*, schisandrin, and gomisin A. As depicted in [**Figure S1**](#SM1){ref-type="supplementary-material"}, G.M2 inhibited mast cell degranulation and this inhibition was slightly greater than schisandrin and gomisin A, and the positive control drug, Dexa, at the same concentration (10 µM). We initially assessed the possible cytotoxicity of G.M2 using MTT assay. G.M2 (0.01--100 µM)-treated mBMMCs, RBL-2H3, and RPMCs were incubated for 8 h. G.M2 did not show cytotoxicity up to 10 µM ([**Figure 1B**](#f1){ref-type="fig"}). Therefore, we decided to use G.M2 up to a concentration of 10 µM for all *in vitro* experiments. Next, we performed further experiments to elucidate the effects of G.M2 on mast cell degranulation. IgE/Ag-sensitized mBMMCs, RBL-2H3, and RPMCs were challenged with DNP-HSA. Pre-treatment with G.M2 (0.1--10 μM) markedly inhibited the release of histamine ([**Figure 1C**](#f1){ref-type="fig"}) and β-hexosaminidase ([**Figure 1D**](#f1){ref-type="fig"}) in a concentration-dependent manner in mBMMCs, RBL-2H3, and RPMCs compared with that in DNP-HSA-challenged cells.

![Effects of Gomisin M2 (G.M2) on mast cell degranulation. **(A)** Chemical structure of G.M2. **(B)** Mouse bone marrow derived mast cells (BMMCs), rat basophilic leukemia cells (RBL-2H3), and rat peritoneal mast cells (RPMCs) (2 × 10^4^ cells/well in a 96-well plate) were pre-treated with or without G.M2 and then incubated with MTT. The absorbance was detected using a spectrophotometer. For mast cell degranulation, anti-DNP (50 ng/ml)-sensitized mBMMCs, RBL-2H3 (5 × 10^5^ cells/well in 12-well plates), and RPMCs (3 × 10^4^ cells/well in a 24-well plate) were pre-treated with or without G.M2 or Dexa for 1 h and then challenged with DNP-HSA (100 ng/ml). **(C)** Histamine levels were detected with a fluorescence plate reader. **(D)** The level of β-hexosaminidase was measured using β-hexosaminidase substrate buffer. Each dataset presented as a graph represents the means ± SEM of three independent experiments. \**p* \< 0.05, compared with the DNP-HSA-challenged group. Dexa: dexamethasone.](fphar-10-00869-g001){#f1}

Effects of G.M2 on Intracellular Calcium Levels in Mast Cells {#s3_2}
-------------------------------------------------------------

Increased calcium is essential for degranulation and cytokine secretion in response to mast cell stimulation ([@B29]). To evaluate the mechanism by which G.M2 suppressed mast cell degranulation, we measured intracellular calcium levels. The inhibitory effects of G.M2 on intracellular calcium release were analyzed using the fluorescent indicator Fluo-3/AM. DNP-HSA-challenged mBMMCs, RBL-2H3, and RPMCs significantly elevated the intracellular calcium levels, and pre-treatment with G.M2 (0.1--10 μM) mitigated the elevation of intracellular calcium levels in a concentration-dependent manner ([**Figure 2**](#f2){ref-type="fig"}).

![Effects of G.M2 on intracellular calcium levels in mast cells. Anti-DNP immunoglobulin E (IgE)--sensitized mBMMCs, RBL-2H3, and RPMCs (3 × 10^4^ cells/well in a 96-well plate) were pre-incubated with Fluo/3AM for 1 h, pre-treated with or without G.M2 for 1 h, and then challenged with DNP-HSA. Intracellular calcium was detected using a fluorescence plate reader. Each dataset presented as a graph represents the means ± SEM of three independent experiments. \**p* \< 0.05, compared with the DNP-HSA-challenged group.](fphar-10-00869-g002){#f2}

Effects of G.M2 on Expression and Release of Inflammatory Cytokines in Mast Cells {#s3_3}
---------------------------------------------------------------------------------

The secretion of inflammatory cytokines, such as TNF-α and IL-6 from activated mast cells, contributes to allergic inflammation ([@B10]). To evaluate the effects of G.M2 on the expression and release of pro-inflammatory cytokines in IgE-sensitized mBMMCs and RBL-2H3, qPCR and ELISA were performed, respectively. Pre-treatment with G.M2 (0.1--10 µM) significantly suppressed the gene expression ([**Figure 3A**](#f3){ref-type="fig"}) and release of pro-inflammatory cytokines ([**Figure 3B**](#f3){ref-type="fig"}) in a concentration-dependent manner compared with that in DNP-HSA-challenged mast cells.

![Effects of G.M2 on expression and release of inflammatory cytokines in mast cells. Anti-DNP IgE--sensitized mBMMCs and RBL-2H3 (5 × 10^5^ cells/well in 12-well plates) were pre-treated with or without G.M2 and Dexa for 1 h and then challenged with DNP-HSA (100 ng/ml). **(A)** The gene expression of inflammatory cytokines was determined by qPCR in mBMMCs and RBL-2H3. **(B)** The release of inflammatory cytokines was measured by enzyme-linked immunosorbent assay (ELISA) in mBMMCs and RBL-2H3. Each dataset presented as a graph represents the means ± SEM of three independent experiments. \**p* \< 0.05, compared with the DNP-HSA-challenged group. Dexa, dexamethasone.](fphar-10-00869-g003){#f3}

Effects of G.M2 on FcεRI-Mediated Signaling Proteins in Mast Cells {#s3_4}
------------------------------------------------------------------

Next, we evaluated the mechanism by which G.M2 inhibited secretion of inflammatory mediators that contribute to the induction and development of allergic inflammation. Therefore, we evaluated the effects of G.M2 on FcεRI-mediated signaling proteins. In mBMMCs, phosphorylations of Lyn, Fyn, Syk, PI3K, PLCγ1, IKKα/β, Akt, and p65 NF-κB were increased by DNP-HSA stimulation. However, G.M2 suppressed the phosphorylation of these proteins compared to DNP-HSA-challenged mBMMCs ([**Figure 4**](#f4){ref-type="fig"}). In order to predict the target molecule, a well-known Src inhibitor PP2 was used as a positive control to evaluate the suppressive effects of G.M2. G.M2 showed an inhibitory effect similar to that of PP2. There is a possibility that G.M2 directly alter the expression of FcεRIα. To check this point, we determined whether G.M2 inhibits FcεRIα expression in mBMMCs and RBL-2H3 using qPCR. The result showed that G.M2 did not inhibit DNP-HSA-upregulated FcεRIα ([**Figure S2**](#SM1){ref-type="supplementary-material"}).

![Effects of G.M2 on FcεRI-mediated signaling proteins in mast cells. Anti-DNP-sensitized mBMMCs (2 × 10^6^ cells/well in 6-well plates) were pre-treated with or without G.M2, Dexa, or PP2 for 1 h and then challenged with DNP-HSA (100 ng/ml). The activation of signaling proteins was assayed by Western blot analysis (p-: phosphorylated). Cropped blots are shown. Full-length blots are presented in [**Figure S3**](#SM1){ref-type="supplementary-material"}. The bands of β-actin and total form were used as loading controls. Each blot is a representative of three independent experiments.](fphar-10-00869-g004){#f4}

Effects of G.M2 on Local and Systemic Anaphylaxis {#s3_5}
-------------------------------------------------

Immediate-type hypersensitivity is associated with mast cell activation ([@B14]). The *in vitro* results led us to evaluate the anti-allergic effects of G.M2 on IgE-mediated PCA and OVA-induced ASA models. These models are suitable to evaluate an anti-allergic inflammatory drug candidate *in vivo* ([@B14]). PCA is the local anaphylaxis animal model, in which allergic reactions are induced by stimulating antigen-challenged mast cells in the dermal layer ([@B16]). PCA reaction in mice was increased in both ears by DNP-HSA challenge, characterized by increased ear swelling and extravasation of Evans blue dye. These reactions were markedly inhibited by oral administration of G.M2 (0.1--10 mg/kg) in a dose-dependent manner ([**Figure 5**](#f5){ref-type="fig"}).

![Effects of G.M2 on IgE-mediated passive cutaneous anaphylaxis (PCA). Mouse ear skin (total *n* = 35, *n* = 5/group) was sensitized with an intradermal injection of anti-DNP IgE (0.5 μg/site) or PBS for 48 h. G.M2 (0.1--10 mg/kg) and Dexa (10 mg/kg) were administered orally, 1 h before intravenous injection of DNP-HSA (1 mg/mouse) and 4% Evans blue (1:1) mixture. Thirty min later, the thickness of both ears was measured, and the ears were collected to measure pigmentation. Dye extravasation was detected using a spectrophotometer. **(A)** Representative photographs of ears. **(B)** Ear thickness. **(C)** Absorbance representing dye extravasations. Each dataset presented as a graph represents the means ± SEM (*n* = 5/group) of two independent experiments. \**p* \< 0.05, compared with the DNP-HSA-challenged group. Dexa, dexamethasone.](fphar-10-00869-g005){#f5}

Systemic anaphylaxis was induced by repetitive administration of OVA and alum adjuvant followed by OVA challenge in mice. Rectal temperatures of the mice were observed for 90 min. During the period 30--60 min, mouse body temperature was decreased while serum histamine level was markedly elevated. Oral administration of G.M2 (0.1--10 mg/kg) significantly increased rectal temperature and reduced the serum histamine level in a dose-dependent manner ([**Figures 6A--C**](#f6){ref-type="fig"}). In addition, G.M2 also suppressed the levels of serum total IgE, OVA-specific IgE, and IL-4, which were elevated after OVA challenge ([**Figures 6D--F**](#f6){ref-type="fig"}).

![Effects of G.M2 on ovalbumin (OVA)-induced active systemic anaphylaxis (ASA). Each mouse (total *n* = 35, *n* = 5/group) was intraperitoneally injected OVA mixture (100 µg of OVA and 2 mg of alum adjuvant) or PBS on days 0 and 7. G.M2 (0.1--10 mg/kg) and Dexa (10 mg/kg) were orally administered on days 9, 11, and 13. On day 14, mice were challenged with an intraperitoneal injection of 200 µg of OVA, and rectal temperature was monitored and then recorded every 10 min for 90 min. Mice were euthanized after 90 min, and blood samples were collected from the abdominal artery. **(A)** Rectal temperature was measured every 10 min for a total of 90 min. **(B)** Rectal temperature of mice at 40 min. **(C--F)** Serum histamine, total IgE, OVA-specific IgE, and IL-4 were detected by ELISA. Each dataset presented as a graph represents the means ± SEM (*n* = 5/group) of two independent experiments. \**p* \< 0.05, compared with the OVA-challenged group. Dexa, dexamethasone.](fphar-10-00869-g006){#f6}

Discussion {#s4}
==========

In the present study, we used various types of murine mast cells (mBMMCs, RBL-2H3, and RPMCs) to evaluate the anti-allergic effect of G.M2, though mBMMCs were predominant cells used in our study. As non-transformed and primary cultured cells, mBMMCs are most widely used cell types for *in vitro* experiments evaluating mast cell function and molecular targets of compounds ([@B33]). Primary cultured cells retain the functions observed *in vivo* and more closely recapitulate the endogenous drug targets physiologically and clinically ([@B7]). Primary cultured cells in new therapeutic drug development can be interchangeable with translational science ([@B5]). Therefore, primary cultured mBMMCs may be a suitable cell type to evaluate the anti-allergic effects and determine the molecular targets of G.M2.

The fruit of *S. chinensis* has been used as a traditional medicine in China, Korea, Japan, and Russia to treat asthma, enuresis, diabetes, dysentery, and other diseases ([@B27]; [@B36]). *S. chinensis* fruit extracts have been reported to possess various pharmacological properties, including anti-oxidation, anti-inflammation, and anti-allergy effects ([@B23]; [@B2]; [@B42]). Many types of compounds were isolated from the fruits of *S. chinensis*, such as lignan, nortriterpenoid, sesquiterpene and phenolic acid; the major identified lignan constituents are schisandrin, gomisin N, and gomisin A, with reported content levels of 0.77%, 0.42%, and 0.17%, respectively ([@B24]; [@B17]). Although the content of G.M2 isolated from *S. chinensis* is less, this extract confers protections from N-acetyl-*p*-aminophenol-induced liver damage, inhibits HIV replication by exhibiting potent anti-HIV activity in H9 T cell lines and reduces proliferation of cancer cells ([@B3]; [@B15]). Before elaborating the anti-allergic properties of G.M2, we initially performed degranulation assay in mBMMCs alongside the well-known anti-allergic and major components, schisandrin and gomisin A. According to our findings, G.M2 inhibited mast cell degranulation to a similar degree as the other components. Therefore, we aimed to evaluate the underlying mechanism of G.M2. Our study demonstrated that G.M2 inhibits mast cell--mediated allergic inflammation *via* inhibition of FcεRI-mediated Lyn and Fyn activation and intracellular calcium levels.

Lyn and Fyn are important intracellular mediators for the initiation of the FcεRI-mediated signaling events in mast cells ([@B37]). Binding of IgE/FcεRI complexes activates both Src family tyrosine kinases Lyn and Fyn. Lyn phosphorylates the tyrosine residues of immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic regions of β and γ subunits. Phosphorylated ITAMs serve as docking sites for activation of the downstream signaling molecule Syk, which subsequently phosphorylates the transmembrane adaptor molecule linker for activation of T cells (LAT). Phosphorylated LAT directly or indirectly binds with cytosolic adaptors, such as Grb2, SLP-76, and SHC, and activates calcium signaling ([@B13]). However, previous study showed that Lyn^-/-^ mice did not show impaired mast cell degranulation ([@B47]; [@B34]). These studies suggested that another Src kinase Fyn plays a complementary role by activating various signaling pathways, including PI3K and Akt/NF-κB ([@B38]). In support of this hypothesis, G.M2 was found to inhibit the phosphorylation of Lyn, Fyn, Syk, IKKα/β, Akt, and NF-κB. Beyond the action, a well-known Src inhibitor PP2 was used to compare the effect of G.M2 on Src kinase, and the results showed that the inhibitory effect of G.M2 was similar to that of PP2. These results indicate that G.M2 suppresses mast cell--mediated allergic inflammation *via* inhibition of FcεRI-mediated Lyn and Fyn activation. According to these results, we propose that the molecular target of G.M2 might be Lyn and Fyn. However, considering the strong inhibition of Lyn and Fyn by G.M2, another possibility was that G.M2 inhibits FcεRI. To evaluate this hypothesis, we tested the effect of G.M2 on the expression of FcεRIα. Our results showed that G.M2 did not alter IgE-elevated FcεRIα expression. From this result, we suggest that the molecular targets of G.M2 might be Lyn and Fyn, as these are important early signaling molecules in mast cell activation.

FcεRI-mediated activation of Lyn and Fyn leads to the activation of the calcium-signaling pathway, which is critical for the calcium release ([@B29]). Increased calcium level is necessary for both degranulation and cytokine secretion ([@B29]). Calcium signaling is induced by receptor-mediated activation of PLCγ. Activated PLCγ cleaves phosphatidylinositol 4,5-biphosphate to generate the secondary messengers IP3 and DAG ([@B29]). Binding of IP3 to its receptor induces intracellular calcium release from the endoplasmic reticulum and Golgi ([@B13]). Moreover, a previous reported that activated PI3K increases IP3 levels, which are associated with intracellular calcium release ([@B11]). Interactions among these signaling molecules are required for the secretion of pro-inflammatory cytokines and mast cell degranulation, which subsequently mediate the allergic inflammation ([@B38]; [@B22]). In our study, G.M2 inhibited phosphorylation of the calcium-signaling molecules, PLCγ, and PI3K and mitigated intracellular calcium levels. This result suggests that G.M2 inhibits mast cell activation by blocking the interaction of Lyn- and Fyn-mediated calcium signaling.

Several reports have provided evidence that intracellular calcium level is associated with pro-inflammatory cytokine secretions by mast cells, which is regulated by transcription factors ([@B20]; [@B1]; [@B28]). Many independent studies have investigated the role of NF-κB, a major transcription factor in mast cells ([@B1]; [@B19]). Activated NF-κB induces inflammatory responses and cytokine synthesis in mast cells, which play important roles in allergic inflammation ([@B19]). Mast cell--derived pro-inflammatory cytokines, such as TNF-α and IL-6, trigger and sustain mast cell inflammatory responses. TNF-α is a potent pro-inflammatory cytokine with a variety of biological functions associated with inflammation, such as tissue remodeling, recruitment of immune cells, and upregulation of adhesion molecules ([@B39]). IL-6 is a soluble mediator, produced in response to allergen that causes T-cell activation and IgE production ([@B43]). Therefore, inhibition of inflammatory cytokines is important for reducing allergic inflammation. G.M2 significantly suppressed the gene expression and release of TNF-α and IL-6 in mBMMCs and RBL-2H3 through inhibition of the Akt/NF-κB pathways. In general, these results suggest that G.M2 exhibits anti-inflammatory effects *via* inhibition of transcription factor and these effects are linked to FcεRI-mediated intracellular calcium release.

Elevated intracellular calcium levels are required for exocytosis of mast cell granules ([@B4]). This process results from FcεRI-mediated mast cell activation and calcium release ([@B13]). Intracellular calcium release causes the fusion of preformed granules with the plasma membrane, which results in secretion of inflammatory mediators, such as histamine, β-hexosaminidase, proteases, proteoglycans, and lipid mediators following mast cell degranulation ([@B4]). These secreted mediators trigger allergic inflammatory responses. Calcium release is central for driving the degranulation of histamine containing vesicles. Histamine is an important effector mediator released upon stimulation ([@B22]). Histamine induces the inflammatory responses *via* vasodilation, increased vascular permeability, hypothermia, and edema ([@B32]). β-Hexosaminidase is a marker of mast cell degranulation that also triggers allergic inflammatory responses ([@B8]). In our results, G.M2 inhibited the release of histamine and β-hexosaminidase in a concentration-dependent manner by inhibiting intracellular calcium levels in various types of mast cells. Previous studies showed that inhibition of mast cell degranulation was linked with the suppression of intracellular calcium levels ([@B1]; [@B19]). Therefore, we suggest that G.M2 inhibited mast cell degranulation by suppressing FcεRI-mediated intracellular calcium levels.

Anaphylaxis is an immediate-type allergic reaction, generally known as the classical pathway, which involves IgE/FcεRI-mediated mast cell activation and subsequent secretion of inflammatory mediators ([@B25]). IgE-mediated PCA and OVA-induced ASA are well-known models for evaluating the anti-allergic effects of compounds based on local and systemic anaphylaxis ([@B21]). PCA is an evanescent cutaneous reaction. Intradermal injection of IgE enhances local allergic reactions, such as increased vascular permeability and plasma extravasation. This allows the leakage of DNP-HSA-bound Evans blue dye at the site of IgE injection. As a result, the amount of dye found in the ear is increased by an allergic reaction ([@B19]). Therefore, G.M2-mediated reduction in leakage of dye and ear thickness in the PCA model suggest an inhibition of allergic reactions. In addition, OVA-sensitized ASA is a generalized allergic reaction manifesting as hypothermia, hypotension, and bronchoconstriction. Repeated administration of OVA sensitization elevates serum histamine and IgE levels and IgE-dependent mast cell activation. The increase in histamine level leads to hypothermia following the OVA challenge ([@B30]). According to our findings, oral administration of G.M2 suppressed these reactions. Thus, we suggest that G.M2 inhibits allergic responses by inhibiting mast cell activation.

Mast cell activation has been broadly studied in allergy for identifying new drug candidates ([@B31]). Anti-histamines, steroids, and anti-IgE drugs have been used as anti-allergic agents for many years ([@B45]). Although these drugs have a rapid effect on mast cell--mediated allergic disease, repeated administration leads to drug resistance and carries side effects, such as drowsiness, dry mouth, vision change, and upset stomach ([@B40]). Therefore, identifying novel anti-allergic drugs is important. Our study provides considerable evidence that G.M2 isolated from *S. chinensis* suppressed mast cell--mediated allergic inflammation by inhibiting FcεRI-mediated Lyn and Fyn activation and intracellular calcium levels. Based on these findings, we propose that G.M2 may represent a novel agent for the management of mast cell--mediated allergic disease.
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